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The pCloDF13-encoded bacteriocin release protein (BRP; Mr 2,871) is essential for the translocation of
cloacin DF13 across the cell envelope of producing Escherichia coli cells. Overproduction of this BRP provokes
lysis (quasilysis) of cells. Construction and analysis of a hybrid BRP-(3-lactamase protein (BRP-Bla)
demonstrated that the BRP contains a lipid modified cysteine residue at its amino terminus and is mainly
located in the outer membrane. The significance of lipid modification for the localization and functioning of the
BRP was investigated. Site-directed mutagenesis was used to substitute the cysteine residue for a glycine residue
in the lipobox of the BRP and the BRP-Bla protein. The mutated BRP was unable to bring about the release
of cloacin DF13 and could not provide the lysis (quasilysis) of host cells. However, the mutated BRP strongly
inhibited the colony-forming ability of the cells, indicating that induction of the mutated protein still affected
cell viability. In contrast to the wild-type BRP-Bla protein, the mutated BRP-Bla protein was mainly located
in the cytoplasmic membrane, indicating that the mutation prevented the proper localization of the protein.
The results indicated that lipid modification of the BRP is required for its localization and release of cloacin
DF13, but not for its lethality to host cells.
Bacteriocin release proteins (BRPs) are low-molecular-
weight proteins required for the translocation for newly
synthesized bacteriocin molecules across both the cytoplas-
mic and outer membrane of producing Escherichia coli cells.
The genes encoding a certain bacteriocin and its correspond-
ing BRP are organized in a single operon and transcribed
from the same promoter, which can be induced by activation
of the host cell SOS response. Moderate induction of a
bacteriocin operon results in strongly increased synthesis
and release of the bacteriocin, whereas strong induction
leads to lysis (marked decline in culture turbidity, also called
quasilysis) of host cells due to the elevated level ofBRP gene
expression (9, 32).
Studies on the molecular basis of BRP-dependent bacte-
riocin export and cell lysis (quasilysis) have indicated that
BRPs directly or indirectly activate the detergent-resistant
phospholipase A, which leads to local permeabilization
zones in the outer membrane and possibly also in the
cytoplasmic membrane (3, 22, 34). These zones function in
the release of bacteriocins and certain other cellular pro-
teins, but might be deleterious to the cells when present in
too large amounts. The precise role of BRPs in the translo-
cation of bacteriocins across the cytoplasmic membrane as
well as their effect on the integrity of this membrane are still
poorly understood.
With the exception of a pColE9-J-encoded BRP, which
seems to be involved in lysis but not in colicin export (15; R.
James, personal communication), all known BRPs are highly
similar in primary structure (4, 6, 9, 10, 29, 40). They contain
a signal peptide with a Leu-X-Y-Cys sequence around the
signal peptide cleavage site. This so-called lipobox, in which
X and Y represent small neutral amino acids, is the consen-
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sus modification sequence for bacterial prolipoproteins (42).
In these proteins, the cysteine residue is modified with
diglyceride prior to their processing by signal peptidase II
(SPase II) between the Y and cysteine residue. Subse-
quently, a third fatty acid is covalently linked to the N-
terminal cysteine.
In a previous paper (23), we described the construction of
,a hybrid protein consisting of the almost complete
pCloDF13-encoded BRP (amino-terminal part) fused to the
mature portion of P-lactamase (carboxyl-terminal part). This
BRP-Bla hybrid protein enabled us to study the acylation,
processing, and subcellular localization of the BRP. The
hybrid protein was shown to be modified with diglyceride
and fatty acids, processed by SPase II, and located primarily
in the outer membrane of E. coli cells (about 70%), whereas
the remainder was found in the cytoplasmic membrane. A
similar distribution was observed in E. coli minicells, which
allow the detection of the mature BRP (31). The BRP-Bla
protein can bring about the release of cloacin DF13, and
overproduction of the hybrid protein leads to quasilysis of
host cells (Luirink et al., submitted for publication).
In this study, we investigated the significance of lipid
modification for the localization and functioning of the BRP.
Site-directed mutagenesis was used to substitute the cyste-
ine residue for a glycine residue in the lipobox of the BRP
and BRP-Bla protein. The mutated BRP was unable to
provoke the release of cloacin DF13 and lysis of host cells.
However, strong induction of mutant BRP expression was
still lethal for cells. The mutation prevented processing of
the BRP-Bla hybrid protein. Unmodified BRP-Bla protein
was mainly located in the cytoplasmic membrane, suggesting
that the mutation prevented the proper localization of the
BRP.
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TABLE 1. E. coli strains used in this study
Strain Genotype Source orreference
N3406 thr leu thi lacY tonA supE 38
FTP4170 A(tonB trpAE) argE(Am) glyVSS F. T. Pagel
BMH71-18 A(lac proAB) supE thi mutL F' 19
lacIq ZAM15 proAB
JM103 AIac pro thi strA supE endA 26
sbcBJ5 hsdR4 F' traD36
proAB lacIq ZAM15
CE1303 F- bio endA recA56 pldA 8
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The various E. coli
strains used in this study are listed in Table 1.
Plasmids pACYC184 (5) and pJN67 (37) were used in the
construction of pJL25 (see also Fig. 3). Plasmid pJL12,
containing the BRP-Bla hybrid gene, has been described
previously (23). Plasmid pINIIIAl (25) was used for expres-
sion of the BRP and mutated BRP gene. Restriction frag-
ments were cloned in the M13 phage vectors mp8 (26) and
mpll (27) for the construction of mutations and DNA
sequencing. Plasmid pPI232, encoding detergent-resistant
phospholipase A, has been described before (8).
Cells were routinely grown in Lab-Lemco broth (Oxoid
Ltd., London, England) supplemented with 0.5% (wt/vol)
sodium chloride and 0.5% (wt/vol) sodium lactate. When
necessary, ampicillin (100 ,ug ml-'), tetracycline (15 ,ug
ml-'), and/or chloramphenicol (30 ,ug ml-1) was added to the
culture medium to select for antibiotic resistance. When
indicated, MgCl2 was added to the culture medium to a final
concentration of 20 mM to prevent BRP-dependent lysis of
cells.
Chemicals and radiochemicals. Globomycin was a gift from
M. Arai, Sankyo, Tokyo, Japan. Mitomycin C was pur-
chased from Kyowa Co., Tokyo, Japan. Purified P-lac-
tamase was a gift from J. Tommassen, Utrecht, The Neth-
erlands. Fixed Staphylococcus aureus cells were purchased
from Calbiochem-Behring, La Jolla, Calif. The radioisotopes
were purchased from Dupont, NEN Research Products,
Boston, Mass.
Oligonucleotide-directed in vitro mutagenesis. The muta-
genic 17-mer 5' TTGCCTGACCTGCGACG 3' was used to
mutate both the pCloDF13-derived BRP gene and the BRP-
Bla hybrid gene at the same position. Mutagenesis was
carried out according to the double primer method as de-
scribed by Zoller and Smith (43), using E. coli BMH71-18
mutL as primary host. Putative mutants were identified by
colony probing, using the 5'-32P-labeled mutagenic primer at
room temperature, followed by successive washes at in-
creasing temperatures (43). To confirm that only the desired
mutation had taken place, the DNA sequence of the mutated
DNA fragment was determined by the dideoxy termination
procedure of Sanger et al. (35), using E. coli JM103 as host
for the M13 bacteriophage.
For mutagenesis of the BRP gene, a 0.4-kilobase BstNI-
ClaI fragment of pEV67, encompassing the complete BRP
gene, was subcloned in M13mp8 (21). Following mutagene-
sis, the mutated BRP DNA fragment was isolated by diges-
tion with EcoRI and HindIII; subsequently, the fragment
was cloned into the polylinker of pINIIIA1.
For mutagenesis of the BRP-Bla hybrid gene, a 0.8-
kilobase PstI fragment of pJL12 carrying a 5'-terminal part
of the BRP-Bla hybrid gene (23) was subcloned in M13mpll.
Following mutagenesis, the fragment was recloned into
pJL12 lacking the PstI fragment.
Other recombinant DNA techniques. For isolation of plas-
mid DNA and M13 double-stranded DNA, the alkaline
method of Bimboim and Doly (1) was used. Transformation
of CaCl2-treated cells was performed as described by Dagert
and Ehrlich (7). All other basic DNA manipulations were
carried out as described by Maniatis et al. (24). DNA-
modifying enzymes were purchased from Bethesda Re-
search Laboratories, Inc., Bethesda, Md., and Pharmacia,
Uppsala, Sweden. All enzymes were used according to the
instructions of the suppliers.
Immunochemical procedures. The hybrid BRP-Bla protein
was detected by immunoblotting carried out essentially as
described by Towbin et al. (36) and using a rabbit antiserum
raised against purified P-lactamase. The amount of cloacin
DF13 in culture supernatant fractions, broken cell suspen-
sions, and subcellular fractions was determined with an
enzyme-linked immunosorbent assay as described previ-
ously (38).
Labeling experiments. Labeling and pulse-chase labeling of
whole cells and in vitro transcription/translation studies
were carried out essentially as described previously (11, 23).
Immunoprecipitation was carried out by the method of
Hayashi and Wu (12), using an antiserum directed against
P-lactamase. When indicated, globomycin dissolved in di-
methyl sulfoxide (10 mg ml-1) was added 5 min prior to
labeling (final concentration, 100 ,ug ml-') to prevent proc-
essing by SPase II (13). Samples were analyzed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE; 20) and autoradiography.
Subcellular localization. For isolation of subcellular frac-
tions, cells were converted to spheroplasts essentially as
described by Witholt et al. (41). Spheroplasts were collected
by centrifugation, and the supematant was taken as the
periplasmic fraction. Subsequently, the spheroplasts were
broken by short periods of sonication, and the membranes
(cytoplasmic and outer membranes) were collected by cen-
trifugation. This fraction was taken as the total membrane
fraction. The supernatant fraction contained the cytoplasmic
fraction. Cytoplasmic and outer membranes were separated
and isolated by isopycnic sucrose density gradient essen-
tially as described by Osborn et al. (30). After centrifugation,
the sucrose density of each fraction was determined and
samples of the various sucrose gradient fractions were
analyzed by SDS-PAGE to examine the distribution of
cytoplasmic and outer membrane proteins.
The presence of mutant and wild-type BRP-Bla protein in
each fraction was determined by measuring the P-lactamase
activity and by immunoblotting; 3-lactamase activity was
assayed spectrophotometrically as described by O'Cal-
laghan et al. (28). Proteins present in periplasmic, cytoplas-
mic, and medium fractions were concentrated by trichloro-
acetic acid precipitation and washed with 90% ethanol prior
to analysis by SDS-PAGE and immunoblotting.
The level of ampicillin resistance of cells was measured by
a plate assay as described by Broome-Smith and Spratt (2) or
a tube assay as described by Kadonaga et al. (16).
RESULTS
Construction of mutant BRP and mutant BRP-Bla. The
amino-terminal cysteine residue of the mature portion of the
pCloDF13-encoded BRP is modified with diglyceride and
fatty acids. To investigate whether this acylation of the
pCloDF13-encoded BRP is essential for its functioning, a
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mutant BRP (pJL18),
BRP-Bla (pJL16)
FIG. 1. Schematic presentation of pJL17, pJL18, pJL12, and
pJL16. The mutation site is shown in detail. imm, 3' End of the gene
encoding immunity protein; BRP, BRP gene; bla, part of the gene
encoding the mature portion of ,-lactamase; Pbla, P-lactamase
promoter; Plppaac tandem lipoprotein/lacZ promoter-operator com-
plex; T1 and T2, terminators of transcription derived from the
cloacin operon. The horizontal arrows indicate the direction of
transcription. The vertical arrow indicates the signal peptide cleav-
age site. The mutated nucleotide is underlined. The lightly hatched
boxes represent the BRP signal sequence, whereas the heavily
hatched boxes represent the mature part of the BRP.
mutation was introduced in the BRP gene by site-directed
mutagenesis. The cysteine residue in the consensus se-
quence for prolipoprotein modification and processing was
converted into a glycine residue (Fig. 1). Subsequently, the
mutant BRP gene was subcloned under control of the Ipp-lac
promoter-operator system in the polylinker of the expression
vector pINIIIAL. The resulting plasmid was designated
pJL18. The wild-type BRP gene was cloned in an identical
manner, which resulted in plasmid pJL17.
To examine the effects of the mutation of Cys+1 to Gly+'
on modification, processing, and subcellular localization, the
BRP-Bla hybrid gene, contained in pJL12, was mutated in
the same way as the BRP gene (Fig. 1). The resulting
plasmid, containing the mutant BRP-Bla hybrid gene under
control of the rather weak P-lactamase promoter, was des-
ignated pJL16.
Expression of the mutant BRP gene and lysis of host cells.
Cultures of cells expressing the wild-type BRP show a
marked decline in turbidity after strong induction. This
decline in culture turbidity (quasilysis) is dependent on the
high expression of the BRP and the presence of the so-called
detergent-resistant phospholipase A and results from dam-
aging of the cell membranes (9, 22). To investigate whether
expression of the mutant BRP had an effect on the cell
culture turbidity, cells of strain FTP4170 harboring pJL18
were cultured and induced with a high concentration of
isopropyl-p-D-thiogalactoside (IPTG; Fig. 2A). A slight
growth inhibition was apparent, but there was no marked
decline in culture turbidity in the logarithmic phase of
growth as observed with cells harboring pJL17, expressing
the wild-type BRP. To study whether strong induction of the
mutant BRP gene eventually results in cell death, cells
harboring pJL18 from an induced culture were plated on
solid broth lacking the inducer IPTG (Fig. 2B). Colony
formation appeared to be inhibited, indicating that expres-
sion of the mutant BRP is potentially a lethal event. The
wild-type BRP encoded by pJL17 showed a strong effect on
colony-forming ability, probably due to lysis of induced cells
(Fig. 2B). These results indicated that induction of the
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FIG. 2. Effect of induction with IPTG on growth (A) and colony-
forming ability (B) of E. coli FTP4170 harboring pJL17 and pJL18.(A) Cells were grown in broth containing ampicillin, and IPTG was
added at zero time. (B) Cells were cultured as in panel A, and at the
indicated time points samples were taken, diluted, and plated on
solid broth agar plates containing ampicillin but lacking IPTG.
Symbols: 0, pJL17, no IPTG added; 0, pJL17, 1 mM IPTG; [1,
pJL18, no IPTG added; *, pJL18, 1 mM IPTG.
mutated BRP gene still causes lethality of host cells, but
without the concomitant cell lysis observed after induction
of the wild-type BRP.
To investigate whether the lethality caused by the mutated
BRP involves activation of the outer membrane detergent-
resistant phospholipase A, plasmids pJL18 and pJL17 were
transferred to strain CE1303. This strain is defective in
detergent-resistant phospholipase A activity, and cultures of
this strain expressing the wild-type BRP do not show the
normally observed decline in culture turbidity (quasilysis;
22). Growth and induction experiments in liquid medium and
on plates were carried out as described above. Strong
induction of the BRP or the mutated BRP hardly affected the
pJL1 7,pJL1 8
imm BRP
n r; /s
lpp/lac 1
_mm BRP bla
pb la T2TT1
CTT TC GTC GCA TG CAG wt BRP (pJL17),
Leu iVaAla Cys Gin BRP-Bla (pJL12)
A
pJL1 2,pJL1 6
CUT GTC GTC GCA GGT CAG
Leu Leu Val Ala Gly Gln
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Eco RI; Kienow; CIAP
ligation
FIG. 3. Cloning strategy for construction of pJL25. Only the
restriction endonuclease cleavage sites used are indicated. Arrows
indicate the direction of transcription. clo, Cloacin gene; imm,
immunity protein gene; BRP, BRP gene; tet, tetracycline resistance
marker; cam, chloramphenicol resistance marker; CIAP, treatment
with calf intestine alkaline phosphatase; Kb, kilobases.
turbidity of cultures, as expected. However, induction of
both BRPs caused inhibition of colony formation on broth
agar plates. A comparable effect on cell viability (colony
formation) was observed when strain CE1303 harboring
pJL18 was complemented with plasmid pPI232, which codes
for the detergent-resistant phospholipase A (8). These re-
sults indicated that the effect on cell viability caused by the
mutant BRP does not involve induction of the detergent-
resistant phospholipase A.
Release of cloacin DF13. To study whether the mutant BRP
was still able to bring about the release of cloacin DF13, a
plasmid was constructed encoding cloacin and its immunity
protein, but lacking the BRP gene (Fig. 3). A 4.1-kilobase
HindIII fragment, containing the genes encoding cloacin and
its immunity protein as well as the promoter of the bacteri-
ocin operon was isolated from pJN67. This plasmid is a
pCloDF13 derivative with an insertion of transposon Tn901
between the genes encoding immunity protein and BRP.
Subsequently, this 4.1-kilobase fragment was cloned in the
polymerase-treated EcoRI site of pACYC184. The resulting
plasmid, pJL25, is compatible with pJL17 and pJL18, which
are derivatives of the pColEl-derived pINIIIAl expression
TABLE 2. Effect of the BRP mutation on release of
cloacin DF13
Concn of Culture Cloacin DF13 Cloacin DF
Plasmida inducer turbid5ty production release
(,uM IPTG)b (66ernm (ljg ml-)c (%)d
pJL17 0 0.57 44.1 3.4
40 0.49 59.0 51.3
1,000 0.36 28.3 61.5
pJL18 0 0.52 43.4 1.1
40 0.53 50.3 1.4
1,000 0.57 54.2 1.0
a E. coli FTP4170 (pJL25) was used as host for the indicated plasmids. Cells
were cultured in broth supplemented with ampicillin, tetracycline, and 20 mM
MgCl2.
b Mitomycin C (500 ng ml-') and IPTG (indicated concentration) were
added at the early exponential growth phase to induce the synthesis of cloacin
DF13 and BRP, respectively.
c The total amount of cloacin DF13 produced was determined 5 h after
induction started by measuring the amounts present in the cells and in the
culture supernatant fraction. The total production of cloacin DF13 in cells
harboring pJL17 after induction with 1,000 ,uM IPTG was lower than after
moderate induction, due to the effect of BRP expression on cell viability.
d Cloacin DF13 released into the medium is given as a percentage of the
total amount (amounts in cells and in medium) of cloacin DF13 produced in
the culture.
vector. Plasmid pJL25 was transferred to E. coli FTP4170.
With this recombinant strain, a high yield of cloacin DF13
production was obtained upon induction of the bacteriocin
promoter with mitomycin C without concomitant lysis of
host cells, due to the absence of the BRP gene. A double
transformant of strain FTP4170, harboring both pJL18 and
pJL25, was used to study the effects of simultaneous induc-
tion of BRP and cloacin DF13 synthesis on cell growth and
bacteriocin release. BRP synthesis was induced with IPTG,
whereas the synthesis of cloacin DF13 was strongly induced
with 500 ng of mitomycin C ml-' (Table 2). The results
showed that high induction of the mutant BRP gene did not
result in the release of cloacin DF13, nor did it affect cell
growth. In contrast, moderate induction of the wild-type
BRP gene was sufficient for significant release of cloacin
DF13 without apparent cell lysis.
Synthesis and processing of the mutant BRP-Bla. The
synthesis and processing of the pCloDF13-encoded BRP is
difficult to study in whole cells of E. coli due to its low
molecular mass, which makes it almost impossible to visu-
alize the polypeptide. Therefore, the effect of the
Cys+'-*Gly+l mutation on synthesis and processing was
studied with the mutant BRP-Bla hybrid protein (see also
reference 23). Cells of E. coli N3406 harboring pJL12 or
pJL16 were labeled in the presence and absence of globo-
mycin, and the immunoprecipitated hybrid proteins were
analyzed by SDS-PAGE (Fig. 4A). When cells with pJL12
were labeled with [35S]methionine, the mature form of the
hybrid protein was easily identified (lane 1). After labeling in
the presence of globomycin, the precursor of the hybrid
protein was detected, as expected (lane 2; see also reference
23). This precursor migrated as a double band (23; see
below). In contrast, following labeling in the presence and
absence of globomycin, the mutant hybrid protein was
detected as a double band (lanes 3 and 4) which migrated
slightly faster than the precursor of the wild-type BRP-Bla
protein. This suggested that the mutation prevented process-
ing of the hybrid protein. The difference in mobility of the
precursors of the wild-type BRP-Bla and mutated BRP-Bla
protein is probably caused by lack of lipid modification of the
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FIG. 4. Autoradiogram of [IS]methionine-labeled and immunoprecipitated BRP-Bla hybrid protein and mutant hybrid protein. (A) Cells
of N3406 harboring pJL12 or PJL16 were labeled for 5 min in the presence or absence of globomycin. Lane 1, pJL12, no globomycin; lane
2, pJL12 plus globomycin; lane 3, pJL16, no globomycin; lane 4, pJL16 plus globomycin. (B) In vitro transcription/translation products
directed by pJL12 (lane 5) and pJL16 (lane 6). Lane 7 shows the result of a control experiment without DNA added. The in vitro system was
tested for the absence of processing of the murein lipoprotein. (C) Pulse-chase labeling of cells of N3406 harboring pJL12 (lanes 8 to 12) or
pJL16 (lanes 13 to 17). Cells were pulse-labeled for 15 s (lanes 8 and 13) and chased for 15 s (lanes 9 and 14), 30 s (lanes 10 and 15), 45 s (lanes
11 and 16), and 60 s (lanes 12 and 17). The precursor and mature species of the (mutant) BRP-Bla protein are connected with bars to indicate
their positions on the various gel panels. prec. d., Precursor doublet of the BRP-Bla protein and mutant hybrid protein; mat., mature form
of the BRP-Bla protein; kDa, kilodaltons.
latter protein. The intensity of the upper and lower bands of
the precursor doublets varied in different experiments (see
discussion).
To further study whether or not the mutated BRP-Bla
hybrid protein is processed and to investigate the relation-
ship between the upper and lower bands of the mutant
BRP-Bla precursor doublet, two experiments were carried
out.
First, in vitro transcription/translation studies were car-
ried out with pJL12 and pJL16 (Fig. 4B). Both the BRP-Bla
and the mutant hybrid proteins migrated at the position of
the precursor of the wild-type hybrid protein. Both proteins
still migrated as a double band. Since processing of precur-
sors does not take place in this type of in vitro experiment,
this indicated that there is no precursor-product relationship
between the two counterparts of the doublet bands.
Second, a pulse-chase experiment was carried out at 30°C
(Fig. 4C). The precursor of the BRP-Bla protein was de-
tected after pulse-labeling for 15 s and was chased into the
mature form (lanes 8 through 12). In contrast, the precursor
of the mutant hybrid protein could not be chased into a
mature form (lanes 13 through 17). Also, a comparable
pulse-chase experiment was carried out at 37°C, in which the
chase period was extended up to 10 min. Virtually the same
results were obtained (not shown).
Taken together, the results indicated that the mutation
prevented processing of the precursor of the hybrid protein.
Apparently, SPase II does not recognize the mutated signal
peptide cleavage site anymore, and alternative processing
by, for instance, SPase I does not occur.
Subcellular localization. In a previous paper the subcellular
localization of the BRP-Bla hybrid protein was studied (23).
About 70% of the protein was detected in the outer mem-
branes and the remainder was mainly located in the cyto-
plasmic membrane, whereas minor amounts were found in
the periplasm and cytoplasm. This localization was in agree-
ment with the localization of the BRP studied in E. coli
minicells (31). Cells expressing the hybrid protein were
resistant to ampicillin, indicating that the P-lactamase por-
tion of the fusion protein protruded into the periplasm (23).
The localization of the mutant BRP-Bla protein was stud-
ied by determining the ,-lactamase activity of subcellular
fractions of strain N3406(pJL16) and by immunoblotting.
About 70% of the total 3-lactamase activity was located in
the total membrane fraction, whereas, in contrast to the
wild-type BRP-Bla protein, a significant P-lactamase activity(about 30% of the total activity) was detected in the periplas-
mic fraction. When the total membrane fraction was sepa-
rated into cytoplasmic and outer membrane fractions, most
of the activity (about 90%) was found to be associated with
the cytoplasmic membranes, whereas the wild-type BRP-Bla
protein was mostly found in the outer membranes (about
75%; Fig. 5). This distribution was confirmed by immuno-
blotting of pooled membrane fractions (Fig. 6). These exper-
iments showed that the mutation prevented the proper
localization of the hybrid protein.
The mutant hybrid protein could not be detected in the
periplasm by immunoblotting (not shown). Possibly, the
P-lactamase activity found in the periplasmic fraction is
derived from unstable ,B-lactamase fragments generated by
proteolytic degradation of mutant hybrid proteins.
The 50% lethal dose of ampicillin for cells harboring pJL16
did not differ from that for cells harboring pJL12, expressing
the wild-type BRP-Bla protein. Apparently, as described for
the wild-type BRP-Bla protein, the P-lactamase portion of
1 2 3 4 5 6 7
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FIG. 5. Distribution of BRP-Bla hybrid protein and mutant hy-
brid protein over outer and cytoplasmic membranes. Membranes
were isolated from cells of N3406 harboring pJL12 or pJL16 and
separated by isopycnic sucrose density gradient centrifugation. The
amount of hybrid protein present in each fraction was estimated by
measuring the P-lactamase activity. The activity is expressed in
arbitrary units. The positions of the outer (O.M.) and cytoplasmic
membranes (C.M.) are indicated by the arrows. The fractions
containing the outer membranes had a sucrose density of 1.23 to
1.25 g ml-' and contained >90% of the major outer membrane
protein markers. Fractions containing cytoplasmic membranes had
a density of 1.15 to 1.18 g ml-'. Symbols: Black bars, BRP-Bla
protein; hatched bars, mutant hybrid protein.
the mutant hybrid protein is fully active and thus protrudes
into the periplasm.
DISCUSSION
NH2-terminal cysteine has a central role in the modifica-
tion and processing of (pro)lipoproteins. During biosynthesis
of lipoproteins, a glyceryl moiety is attached to the sulfhy-
dryl group in the cysteine residue, followed by 0-acylation
of glyceryl cysteine. Subsequently, the modified prolipopro-
tein is processed by SPase II and the free NH2 group of
cysteine is N-acylated by a fatty acid, which results in a fully
modified and processed lipoprotein (42).
In a previous paper, we presented evidence that the
pCloDF13-encoded BRP is a lipoprotein which is processed
by- SPase II. A BRP-Bla hybrid protein was used to facilitate
the study of BRP modification and processing since we were
not able to visualize the BRP due to its low molecular mass.
BRP-BIa
mutant
BRP- Bla
34kDa-
_ ,.
32 kDa-
I I
O.M. C.M. O.M. C.M.
FIG. 6. Immunoblotting of BRP-Bla hybrid protein and mutant
hybrid protein present in outer and cytoplasmic membranes. Mem-
branes of cells expressing wild-type BRP-Bla (pJL12) and mutant
BRP-Bla (pJL16) proteins were separated as described in the legend
to Fig. 5, and outer and cytoplasmic membranes were pooled. O.M.,
Outer membranes; C.M., cytoplasmic membranes.
During the course of our study, Cavard et al. (3) and
Pugsley and Cole (33) used site-directed mutagenesis to
change the lipobox of the pColA- and pColE2-encoded BRPs
(Cal and CelB), respectively. Cavard et al. (3) replaced the
cysteine at the + 1 position for a threonine and the alanine at
the -1 position for a proline in two different constructs.
Both mutations prevented normal modification and process-
ing, and the mutant BRPs proved not to be functional in
outer membrane detergent-resistant phospholipase A-depen-
dent lysis and export of colicin A. Pugsley and Cole (33)
substituted the cysteine at the + 1 position of the pColE2
BRP for an arginine. This mutation prevented processing of
the pColE2-encoded BRP precursor. However, this mutant
protein was able to stimulate the export of colicin E2, albeit
to a lesser extent, and it caused a delayed phospholipase
A-dependent lysis of cells.
In this study, the NH2-terminal cysteine residue of the
pCloDF13-encoded BRP was changed into a glycine residue
by oligonucleotide-directed mutagenesis and the effects of
this mutation on the functioning of the BRP were investi-
gated. Furthermore, the same mutation was created in the
BRP-Bla hybrid gene to facilitate the study of the effects of
modification on processing and subcellular localization. The
experiments showed that the mutant BRP was not functional
with respect to release of cloacin DF13 and lysis of host
cells. These results agree mostly with those obtained by
Cavard and co-workers. However, induction of the mutant
BRP gene caused lethality of host cells as observed after
growing of induced cells on broth agar plates, but this
lethality was found to be independent of detergent-resistant
phospholipase A.
In contrast to the wild-type BRP-Bla protein, the mutant
BRP-Bla protein was not processed. We assume that the
constructed mutation prevents processing of the mutant
BRP by SPase II and also by SPase I, despite the creation of
the putative SPase I cleavage site Ala-Gly (39). Alternative
processing by SPase I has been shown to take place with one
of the mutant pColA BRPs (Cys+'-*Thr+1). The mutant
pColE2 BRP was not processed either, despite the suitable
SPase I cleavage site created in this protein (39).
Expression of the mutant BRP-Bla protein resulted in a
doublet protein band migrating slightly faster than the wild-
type BRP-Bla precursor. Both bands of the doublet repre-
sented the mutant precursor as confirmed by pulse-chase
experiments and in vitro transcription/translation studies.
The formation of doublet bands is not an unusual feature for
(mutant) pre-p-lactamase and is believed to be the result of
differences in conformation (18).
Most of the mutant BRP-Bla precursor protein was found
to be associated with the cytoplasmic membranes. This is in
contrast to the wild-type mature BRP-Bla protein which is
mainly located in the outer membranes. Unfortunately,
expression of the hybrid BRP-Bla gene is too low to confirm
these results by immunoelectron microscopy studies (23).
However, we feel that the data obtained by "conventional"
fractionation methods are reliable, taking the very low
abundance of the hybrid proteins into account. The most
plausible explanation for the aberrant localization of the
mutant hybrid protein is that the uncleaved signal sequence
anchors the protein in the cytoplasmic membrane, as has
been observed earlier for uncleaved pre-p-lactamase (17,
18). Like the ,-lactamase portion of the wild-type BRP-Bla
protein (23), the ,-lactamase portion of the mutant hybrid
protein probably protrudes into the periplasm since this
protein is fully active in the protection of cells against
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ampicillin. Cytoplasmic (pre) P-lactamase is enzymatically
inactive (16).
We assume that the results obtained with the mutant
BRP-Bla hybrid protein can be extrapolated to the mutant
BRP. Therefore, the lack of processing and the aberrant
subcellular localization might explain why this protein is
unable to bring about the release of cloacin DF13 and lysis of
cells.
The pCloDF13-encoded BRP possesses three functions
that can be distinguished. It can bring about the release of
cloacin DF13, it can cause a marked decline in culture
turbidity (lysis) in liquid medium, and it inhibits colony
formation of induced host cells on solid medium. Based on
our results and those of others (3, 33), we assume that the
lipid moiety is essential for targeting of the BRP to the outer
membrane and that the mature polypeptide structure is
required for activation of the detergent-resistant phospholi-
pase A. Furthermore, the lethality (inhibition of colony
formation) caused by the BRP is a phospholipase-indepen-
dent effect which might involve the BRP signal sequence.
Lipid modification does not seem to be essential for proper
localization and functioning of the pColE2-encoded BRP
(33). Possibly, the peptide part of this BRP also has affinity
for the outer membrane as suggested for unmodified Braun's
prolipoprotein (14). The BRP signal sequence, which seems
to be extremely stable for the pColA- and pColE2-encoded
BRPs, could play a role in killing of host cells. The accumu-
lation of this sequence or the interaction between the signal
sequence and the cytoplasmic membrane or both could be
deleterious to the cells. Recently, we observed that a mutant
BRP, containing only four amino-terminal amino acid resi-
dues, still causes lethality of host cells on plates, but is
unable to cause lysis of cells in liquid medium and to bring
about release of cloacin DF13 (submitted for publication).
We are currently investigating the role of the pCloDF13 BRP
signal sequence in more detail by fusing it directly to the
mature part of ,-lactamase.
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